$IVST Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a Conglomerate with operations in commercial and industrial products and services, and biotechnology, sold its most recent six-figure revenue contract last week, and notes that its Call Center is now generating double the baseline revenue it was generating just a few months ago, when it was acquired. The division is now pacing $4.5 million in annual revenue.
“Sally Emch, our President of Call Center Operations, has doubled the center’s baseline revenue since the acquisition, and the Shepherd team just closed another six figure sale at the end of last week,” said Dan Martin, CEO of Innovest. “The StemVax patent approval has been a recent focus of excitement, and our C&I Group is also really hitting stride. Working together well, closing big competitive sales, and excited to push through the quarter with momentum. The team is so excited at the support our shareholders have shown, and the enthusiasm is something I wish everyone could see.”
https://globenewswire.com/news-release/2018/0...rowth.html
“Sally Emch, our President of Call Center Operations, has doubled the center’s baseline revenue since the acquisition, and the Shepherd team just closed another six figure sale at the end of last week,” said Dan Martin, CEO of Innovest. “The StemVax patent approval has been a recent focus of excitement, and our C&I Group is also really hitting stride. Working together well, closing big competitive sales, and excited to push through the quarter with momentum. The team is so excited at the support our shareholders have shown, and the enthusiasm is something I wish everyone could see.”
https://globenewswire.com/news-release/2018/0...rowth.html
